Ajanta Pharma Receives US FDA Form 483 With Five Observations at Paithan Plant

Ajanta Pharma Limited ( (IN:AJANTPHARM) ) has provided an announcement.

Ajanta Pharma has announced that the U.S. Food and Drug Administration has completed an inspection of its Paithan manufacturing facility in Maharashtra, conducted from April 13 to April 21, 2026. The inspection concluded with the issuance of a Form 483 containing five observations, indicating areas where the regulator believes the facility may require corrective action.

The company said it will submit a response to the U.S. regulator within the stipulated timeline, a critical step in addressing compliance concerns and maintaining its position in the U.S. market. Stakeholders are likely to monitor how effectively Ajanta remediates the observations, as the outcome can influence future regulatory risk, supply continuity, and the company’s standing in regulated export markets.

More about Ajanta Pharma Limited

Ajanta Pharma Limited is an India-based pharmaceutical company headquartered in Mumbai, operating manufacturing facilities including a site at Paithan in Maharashtra. The company develops and produces pharmaceutical formulations for regulated markets, with a presence in key international jurisdictions such as the U.S., making regulatory compliance central to its business and market access.

Average Trading Volume: 11,309

Technical Sentiment Signal: Strong Buy

Current Market Cap: 360.8B INR

See more insights into AJANTPHARM stock on TipRanks’ Stock Analysis page.